133 related articles for article (PubMed ID: 21374569)
1. Solutions for lipophilic drugs: a biodegradable polymer acting as solvent, matrix, and carrier to solve drug delivery issues.
Asmus LR; Gurny R; Möller M
Int J Artif Organs; 2011 Feb; 34(2):238-42. PubMed ID: 21374569
[TBL] [Abstract][Full Text] [Related]
2. Solutions as solutions--synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulate sustained-release parenterals.
Asmus LR; Gurny R; Möller M
Eur J Pharm Biopharm; 2011 Nov; 79(3):584-91. PubMed ID: 21820511
[TBL] [Abstract][Full Text] [Related]
3. Single processing step toward injectable sustained-release formulations of Triptorelin based on a novel degradable semi-solid polymer.
Asmus LR; Kaufmann B; Melander L; Weiss T; Schwach G; Gurny R; Möller M
Eur J Pharm Biopharm; 2012 Aug; 81(3):591-9. PubMed ID: 22561956
[TBL] [Abstract][Full Text] [Related]
4. Injectable formulations for an intravitreal sustained-release application of a novel single-chain VEGF antibody fragment.
Asmus LR; Grimshaw JP; Richle P; Eicher B; Urech DM; Gurny R; Möller M
Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):250-60. PubMed ID: 25779352
[TBL] [Abstract][Full Text] [Related]
5. In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer.
Asmus LR; Tille JC; Kaufmann B; Melander L; Weiss T; Vessman K; Koechling W; Schwach G; Gurny R; Möller M
J Control Release; 2013 Feb; 165(3):199-206. PubMed ID: 23220105
[TBL] [Abstract][Full Text] [Related]
6. A novel in situ forming drug delivery system for controlled parenteral drug delivery.
Kranz H; Bodmeier R
Int J Pharm; 2007 Mar; 332(1-2):107-14. PubMed ID: 17084049
[TBL] [Abstract][Full Text] [Related]
7. Sucrose acetate isobutyrate as an in situ forming system for sustained risperidone release.
Lu Y; Yu Y; Tang X
J Pharm Sci; 2007 Dec; 96(12):3252-62. PubMed ID: 17721936
[TBL] [Abstract][Full Text] [Related]
8. Poly(3-hydroxybutyrate-co-epsilon-caprolactone) copolymers and poly(3-hydroxybutyrate-co-3-hydroxyvalerate-co-epsilon-caprolactone) terpolymers as novel materials for colloidal drug delivery systems.
Pignatello R; Musumeci T; Impallomeni G; Carnemolla GM; Puglisi G; Ballistreri A
Eur J Pharm Sci; 2009 Jun; 37(3-4):451-62. PubMed ID: 19504659
[TBL] [Abstract][Full Text] [Related]
9. Ocular biocompatibility of novel Cyclosporin A formulations based on methoxy poly(ethylene glycol)-hexylsubstituted poly(lactide) micelle carriers.
Di Tommaso C; Torriglia A; Furrer P; Behar-Cohen F; Gurny R; Möller M
Int J Pharm; 2011 Sep; 416(2):515-24. PubMed ID: 21219997
[TBL] [Abstract][Full Text] [Related]
10. Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol.
Ahmed TA; Ibrahim HM; Ibrahim F; Samy AM; Kaseem A; Nutan MT; Hussain MD
J Pharm Sci; 2012 Oct; 101(10):3753-62. PubMed ID: 22753324
[TBL] [Abstract][Full Text] [Related]
11. Simple measurements for prediction of drug release from polymer matrices - Solubility parameters and intrinsic viscosity.
Madsen CG; Skov A; Baldursdottir S; Rades T; Jorgensen L; Medlicott NJ
Eur J Pharm Biopharm; 2015 May; 92():1-7. PubMed ID: 25668778
[TBL] [Abstract][Full Text] [Related]
12. Hyperbranched polymers as drug carriers: microencapsulation and release kinetics.
Suttiruengwong S; Rolker J; Smirnova I; Arlt W; Seiler M; Lüderitz L; Pérez de Diego Y; Jansens PJ
Pharm Dev Technol; 2006 Feb; 11(1):55-70. PubMed ID: 16544909
[TBL] [Abstract][Full Text] [Related]
13. Investigations on the lyophilisation of MPEG-hexPLA micelle based pharmaceutical formulations.
Di Tommaso C; Como C; Gurny R; Möller M
Eur J Pharm Sci; 2010 Apr; 40(1):38-47. PubMed ID: 20184955
[TBL] [Abstract][Full Text] [Related]
14. Structure formation and characterization of injectable drug loaded biodegradable devices: in situ implants versus in situ microparticles.
Kranz H; Bodmeier R
Eur J Pharm Sci; 2008 Jul; 34(2-3):164-72. PubMed ID: 18501569
[TBL] [Abstract][Full Text] [Related]
15. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content.
Budhian A; Siegel SJ; Winey KI
Int J Pharm; 2007 May; 336(2):367-75. PubMed ID: 17207944
[TBL] [Abstract][Full Text] [Related]
16. Influence of the drug compatibility with polymer solution on the release kinetics of electrospun fiber formulation.
Zeng J; Yang L; Liang Q; Zhang X; Guan H; Xu X; Chen X; Jing X
J Control Release; 2005 Jun; 105(1-2):43-51. PubMed ID: 15908033
[TBL] [Abstract][Full Text] [Related]
17. Effect of drug type on the degradation rate of PLGA matrices.
Siegel SJ; Kahn JB; Metzger K; Winey KI; Werner K; Dan N
Eur J Pharm Biopharm; 2006 Nov; 64(3):287-93. PubMed ID: 16949804
[TBL] [Abstract][Full Text] [Related]
18. The interplay of membrane formation and drug release in solution-cast films of polylactide polymers.
Ma D; McHugh AJ
Int J Pharm; 2010 Mar; 388(1-2):1-12. PubMed ID: 20025948
[TBL] [Abstract][Full Text] [Related]
19. Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization.
Camargo JA; Sapin A; Nouvel C; Daloz D; Leonard M; Bonneaux F; Six JL; Maincent P
Drug Dev Ind Pharm; 2013 Jan; 39(1):146-55. PubMed ID: 22397675
[TBL] [Abstract][Full Text] [Related]
20. PHEA-PLA biocompatible nanoparticles by technique of solvent evaporation from multiple emulsions.
Cavallaro G; Craparo EF; Sardo C; Lamberti G; Barba AA; Dalmoro A
Int J Pharm; 2015 Nov; 495(2):719-27. PubMed ID: 26410757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
